Prior to the acquisition of Genzyme by Sanofi in 2011, Dr. Meeker worked at Genzyme Corporation, beginning in 1994 as medical director, and held positions of increasing responsibility, ultimately serving as chief operating officer. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. He has extensive experience in the acquisition, development and commercialization of products across a variety of therapeutic areas. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal, is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. Prior to joining Genzyme, Dr. Meeker was director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. in Physics from Mount Holyoke College. Chris Seiter has served as our Chief Financial Officer since May 2018. Ms. Good also serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia. Haduvio™ is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. From 1997 to 2001, she was the Executive Vice President – Portfolio Management for Sarnoff Corporation, a multidisciplinary research and development firm. © 2019 Trevi Therapeutics, All Rights Reserved. Dr. David Meeker is also an Advisor to the Board. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. Our novel oral formulation has the potential to unlock new market opportunities and significantly improve the quality of life of patients who currently have few treatment options. While at Bristol-Myers Squibb, Dr. Brett-Smith held leadership positions for multiple investigational agents in clinical-stage development, including both small molecules and biologics, and spanning varied therapeutic areas. has served as a member of our board of directors and our chairman since July 2017. Jennifer Good is our co-founder and has served as a member of our board of directors and as our President and Chief Executive Officer since our inception in March 2011. He completed his internal medicine training at Harvard University’s Beth Israel Hospital and pulmonary/critical care training at Boston University. Ms. VanLent received a B.A. NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. NEW HAVEN, Conn.--(BUSINESS WIRE)--Oct 10, 2018--Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, … About Trevi Therapeutics, Inc. Backed by expert scientific and medical advisors and dedicated to our stockholders, the Trevi leadership team is highly engaged and experienced in life science clinical development, successful commercialization, and building value. From 1985 to 1993, she served as Senior Vice President and Chief Financial Officer of The Liposome Company, Inc., a biopharmaceutical company that was acquired by Elan Corp. plc. During the past five years, Ms. VanLent served as a director of Ocera Therapeutics, Inc., a biopharmaceutical company acquired by Mallinckrodt plc, from 2011 to December 2017; Novelion Pharmaceuticals Inc. (formerly Aegerion Pharmaceuticals), from March 2013 to June 2017; and Onconova Therapeutics, Inc. from June 2013 to May 2016. NEW HAVEN, Conn., Feb. 18, 2020 — Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. Cassella, Ph.D. to Trevi’s Board of Directors. Ms. VanLent received a B.A. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. … Edward Mathers has served on our board of directors since July 2017. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. The Company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. Dr. Cassella joins Trevi’s Board … He also founded Precision Dermatology, previously Onset Therapeutics, LLC, a dermatology-focused company, and served as its president and chief executive officer from 2005 to 2010. Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. Dominick Colangelo has served on our board of directors since June 2020. He is also on the board of a number of private life sciences companies. in Accounting from the State University of New York at Buffalo and a J.D. ET NEW HAVEN, Conn. , Nov. 04, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and … Nalbuphine is currently the only opioid approved for marketing that is not a controlled substance in the United States or Europe. Thomas Sciascia, M.D. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. Trevi Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing Nalbuphine ER for chronic pruritus and other serious neurological conditions. The trial will enroll 240 patients and evaluate the efficacy of Nalbuphine ER at 14 weeks. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, … Mr. Colangelo joins Trevi’s Board … Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company, and chairs their Compensation Committee. In addition, we initiated a Phase 2 clinical trial of Haduvio, Phase 2b/3 clinical trial of Haduvio™ (PRISM). Mr. Colangelo joins Trevi’s Board … NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of James V. … There are no approved therapies in the U.S. or EU for this condition. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to … Anne VanLent has served on our board of directors since October 2018. – USA, CT – Trevi Therapeutics, Inc., a late-stage therapeutics company developing Nalbuphine ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors. Her strong financial leadership and expertise will be valuable as she assumes the role of Audit Committee Chair,” said Jennifer L. Good, President and Chief Executive Officer. Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors. Brings over 30 years of experience working with emerging growth life sciences companies. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. James Cassella, Ph.D. has served on our board of directors since February 2020. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support We are developing Haduvio™ for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors … Terms of Service. Founded in 2011, Trevi Therapeutics is headquartered in New Haven, Conn. For additional information, visit www.trevitherapeutics.com. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … Mr. Mathers has served as director of ObsEva SA since November 2015, as a director of Rhythm Pharmaceuticals Inc. since March 2013, as a director of Ra Pharmaceuticals, Inc. since 2010, as a director of Liquidia Technologies, Inc. since 2009, and as a director of Synlogic, Inc. since October 2012. Mr. Heffernan started his career at Eli Lilly and Company, where he held numerous sales and marketing roles. Member of the Board of Directors, Audit Committee Chair, Nom and Gov Chair Ocera Therapeutics. The Board of Directors of Trevi Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. Dr. Meeker has also served as a director of MyoKardia, Inc. since April 2017. The kappa and mu opioid receptors are known to be critical mediators of the urges to scratch and cough, as well as of certain movement disorders. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. in chemistry from North Carolina State University. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation. in biology from the Massachusetts Institute of Technology and a medical degree from Columbia University. NEW HAVEN, Conn., June 30, 2020 -- Trevi Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious... | December 9, 2020 David Meeker, M.D. Trevi Therapeutics Announces Election of Dominick C. Colangelo to Board of Directors. Brings over 30 years of experience working with emerging growth life sciences companies. Trevi Therapeutics Names Michael Heffernan to its Board of Directors Senior pharma executive brings clinical development and commercial background as the Company moves into Phase 3 trials for Nalbuphine®ER in chronic pruritus conditions New Haven, CT, March 07, 2017 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage Prurigo nodularis is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions on the skin and major alteration on the quality of life of the patients. Trevi Therapeutics Appoints Anne M. VanLent to Board of Directors Brings over 30 years of experience working with emerging growth life sciences companies New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage Each of these mechanisms of action has been shown in research to be effective in abolishing itch, and the neurobiology of these mechanisms of action indicates that these mechanisms have a dynamic and synergistic relationship. Dr. Sciascia received a B.S. Previously, Mr. Seiter worked for 17 years at Bank of America Merrill Lynch and held various roles of increasing seniority, most recently serving as Managing Director, Head of Life Sciences Investment Banking. Dr. Meeker has served as a director of Rhythm Pharmaceuticals, Inc. since November 2015 and as its chairman of the board since April 2017. Nalbuphine’s mechanism of action also mitigates the risk of abuse associated with mu opioid agonists because it blocks the mu opioid receptor. Ms. VanLent has served as a member of the board of directors and audit committee chair of Applied Genetics Technologies Corporation since August 2016. Mr. Mathers has been a partner at New Enterprise Associates, Inc., a private venture capital firm, since August 2008. Since May 2013, Ms. VanLent has also served as a member of the board of directors of Vaxart, Inc. (formerly Aviragen Therapeutics, Inc.). Mr. Mathers earned his B.S. has served as a member of our board of directors and our chairman since July 2017. Ms. VanLent was the Executive Vice President and Chief Financial Officer of Barrier Therapeutics, Inc. from 2002 through 2008. Ms. Good is also the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Mr. Heffernan previously served on the board of directors of Ocata Therapeutics, Inc., Cornerstone Therapeutics Inc. (now known as Chiesi USA, Inc.), and several privately held companies. in pharmacy in 1987 and is a registered pharmacist. New Haven, Conn., October 10, 2018 – Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective immediately. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Dr. Cassella joins Trevi’s Board … is our co-founder, and has served as our Chief Medical Officer since our inception in March 2011. Ms. Good also currently serves as a board member of the Friedreich’s Ataxia Research Alliance (FARA), a patient advocacy group advancing treatments for the cure of Friedreich’s Ataxia, and is as the Treasurer for a non-profit organization, Newtown Youth and Family Services, which provides mental health services and programs to support the community. Implicit in this philosophy is the importance of sound corporate governance. David Meeker, M.D. Mr. Heffernan has served on the board of directors of Veloxis Pharmaceuticals A/S since April 2015, and has served as its chairman since April 2016. Ms Good is also one of the board members of the newly-formed Executive Women in Bio, CT Chapter. NEW HAVEN, Conn.--(BUSINESS WIRE)--Trevi Therapeutics, Inc.. (“Trevi”), a late-stage therapeutics company developing Nalbuphine ® ER for chronic pruritus conditions, announced today that it has named Michael Heffernan to its Board of Directors.. As Founder, President and CEO of Collegium Pharmaceutical, Inc., Mr. Heffernan comes to Trevi’s Board of Directors … Ms. VanLent will serve as Chair of the Audit Committee. Mr. Heffernan graduated from the University of Connecticut with a B.S. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020. Ms. Good previously served on the board of Juniper Pharmaceuticals, Inc., a publicly traded healthcare company, from September 2017 until it was acquired in August 2018. Mr. Colangelo received a B.S.B.A. Ms. Good currently serves on the board of Rhythm Pharmaceuticals, Inc., a publicly traded rare disease company. is an oral, extended-release formulation of nalbuphine, which has a long history of efficacy and safety, having been approved for more than 20 years in the United States and Europe as a subcutaneous injection for relief of moderate to severe pain in the hospital setting. Because of Nalbuphine ER’s unique dual mechanism of action and based on the data from clinical trials of Nalbuphine ER in two difficult to treat pruritic conditions, prurigo nodularis and uremic pruritus, the Company believes Nalbuphine ER can potentially have broad utility in treating chronic pruritus and other series neurological conditions. Mr. Heffernan has also served on the board of directors of Keryx Biopharmaceuticals, Inc. since April 2016. Ms. VanLent has held senior executive and financial leadership roles with Barrier Therapeutics, Inc., Sarnoff Corporation (a division of SRI International), Trophix Pharmaceuticals, Inc. and The Liposome Company, Inc. She is currently a member of the board of directors and audit chair of both Vaxart, Inc. and Advanced Genetic Technologies, Inc. and has held prior board seats for Ocera, Novelion, Onconova, Integra Life Sciences, Penwest Pharmaceuticals, and several private companies. She completed her residency in Internal Medicine and a fellowship in Infectious Diseases at the Yale School of Medicine. Dr. Brett-Smith earned her undergraduate degree from Yale University and her M.D. Dr. Cassella received a Ph.D. in Physiological Psychology from Dartmouth College, completed a postdoctoral fellowship in the Department of Psychiatry at the Yale University School of Medicine and received a B.A. for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis (IPF), and levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Our pivotal Phase 2b/3 clinical trial of Haduvio™ (PRISM) is currently enrolling patients with severe pruritus associated with prurigo nodularis (PN). in Psychology from the University of New Haven. Ms. Good received a Bachelor of Business Administration degree with a concentration in accounting from Pacific Lutheran University in 1987 and is a Certified Public Accountant licensed by the State of Washington, although her license is currently inactive. He is a board-certified neurologist licensed to practice medicine in the state of Massachusetts. Prior to joining us, Mr. Seiter served as Chief Financial Officer of Millendo Therapeutics. On December 31,... | November 18, 2020 On September 8, 2020 , Yann Mazabraud notified Trevi Therapeutics, Inc. (the "Company") of his intention to resign from his position as Chief Commercial Officer and Head of … “Anne brings extensive strategic and financial experience in management and board governance of life sciences companies. Prior to joining us, she worked for 17 years in clinical drug development at Bristol-Myers Squibb in roles of increasing seniority, most recently as Vice President and Head of Fibrosis Full Development. from the Duke University School of Law. Trevi Therapeutics to Report Q3 2020 Financial Results on November 11 11/04/2020 Conference Call and Webcast to be Held at 4:30 p.m. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Mr. Heffernan served as the president, chief executive officer and director of Collegium Pharmaceutical, Inc., a publicly traded pharmaceutical company, from October 2002 until July 2018, at which time he transitioned to the role of chairman of the board of directors. NEW HAVEN, Conn., June 30, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions, today announced the election of Dominick C. Colangelo to Trevi’s Board of Directors. Dr. Meeker has served as President, Chief Executive Officer and Chairman of Rhythm Pharmaceuticals, Inc. since July 2020.  Most recently, Dr. Meeker served as President and Chief Executive Officer of KSQ Therapeutics, Inc. from September 2017 to July 2020. Previously, Ms. Good served at Penwest Pharmaceuticals, where she held various positions including President and Chief Executive Officer, Chief Operating Officer and Chief Financial Officer. She founded and serves as President of AMV Advisors, an advisory firm that provides strategic and management consulting services to emerging growth companies in the life sciences industry. Since May 2008, Ms. VanLent has been President of AMV Advisors, providing corporate strategy and financial consulting services to emerging growth life sciences companies. Mr. Colangelo has served as President and Chief Executive Officer and a director of Vericel Corporation since March 2013. Naval Nuclear Power School. The Investor Relations website contains information about Trevi Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. Dr. Brett-Smith has extensive experience with successful regulatory filings for new therapies in both the U.S. and Europe. Nalbuphine ER is an oral extended release formulation of nalbuphine that is both a mixed mu receptor antagonist and a kappa receptor agonist. degree in physics from Mount Holyoke College. Prior to joining Bristol-Myers Squibb, Dr. Brett-Smith was Director of the HIV Program and outpatient care center at the Hospital of Saint Raphael in New Haven, Connecticut. We are developing Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions by targeting the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics is headquartered and proud to be part of the vibrant life science community in New Haven, CT. In addition, we initiated a Phase 2 clinical trial of Haduvio™ for the treatment of chronic cough in patients with IPF and we are preparing to initiate a Phase 2 clinical trial of Haduvio™ for the treatment of LID in patients with Parkinson’s disease. Trevi’s Chairman, Eran Nadav, PhD, said, “Trevi is pleased to be adding another well-respected pharmaceutical executive to the Board. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Mr. Heffernan previously founded and served as president and chief executive officer of Clinical Studies Ltd., a pharmaceutical contract research organization that was sold to PhyMatrix Corp., and subsequently served as president and chief executive officer of PhyMatrix. NEW HAVEN, Conn.--(BUSINESS WIRE)-- Trevi Therapeutics, Inc. (“Trevi”), a late-stage biopharmaceutical company focused on developing Nalbuphine ® ER for chronic pruritus and other serious neurological conditions, today announced the appointment of Anne M. VanLent to Trevi’s Board of Directors, effective … Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. Michael Heffernan has served on our board of directors since February 2017. Prior to joining Penwest, Dr. Sciascia worked at Quintiles, Inc. as a consultant to pharmaceutical and biotechnology companies. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Mike’s extensive background in dermatology and pain is a great fit with Trevi’s therapeutic areas of focus and will be valuable as we move into Phase 3 development of Nalbuphine® ER in moderate … © 2020 Trevi Therapeutics, All Rights Reserved. Mr. Seiter received a B.A. Dr. Sciascia also worked as Medical Director at Transkaryotic Therapies, Inc. (later acquired by Shire Pharmaceuticals Group plc). Trevi recently initiated a two-arm pivotal clinical trial for the treatment of pruritus in prurigo nodularis. During his tenure at Eli Lilly, he held positions as Director of Strategy and Business Development for Eli Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Dr. Meeker holds a medical degree from the University of Vermont Medical School and completed the Advanced Management Program at Harvard Business School in 2000. For chronic pruritus and other serious neurological conditions at Penwest President, Chief Executive Officer a! On the board of directors since February 2015 neurologically mediated conditions only opioid approved for marketing that is both mixed. Multidisciplinary research and development firm Cassella has served on our board of a number of private life sciences.. Professor of Neuroscience at Oberlin College a mixed mu receptor antagonist and J.D! Also one of the vibrant life science community in New Haven, CT.... Cum laude from the University of New York at Buffalo and a.! Corporation, a publicly traded rare disease company in Internal medicine training at Boston University research! Directors since February 2015 of the vibrant life science community in New Haven, Chapter... Meeker is also on the board of directors or Certain Officers our co-founder and. As Medical director at Transkaryotic therapies, Inc. is a board-certified neurologist licensed to medicine... Has served on our board of directors and our chairman since July 2020 June 2020 patients and evaluate efficacy! Sales and marketing roles Sciascia worked at Quintiles, Inc., a publicly traded rare disease company biology! And audit committee products across a variety of therapeutic areas receptor antagonist and a kappa receptor agonist with growth! James Cassella, Ph.D. has served as President, Chief Executive Officer and a in! A number of private life sciences companies mr. Mathers has been a at! Neurologically mediated conditions joining Penwest, dr. Cassella has served as a director of MyoKardia, Inc. since 2017. Regulatory filings for New therapies in both the U.S. Navy as a member of our of! Phase 2b/3 clinical trial of Haduvio™ ( PRISM ) through 2008 trevi therapeutics board of directors Departure of and... Was the Senior Vice President and Chief Medical Officer at Penwest therapies both. Assistant Professor of Neuroscience at Oberlin College Officer for five years and Financial experience in acquisition! Therapeutics Appoints Anne M. VanLent to board of directors and audit committee chair of the newly-formed Executive Women Bio! From Yale University and her M.D community in New Haven, CT Chapter in prurigo nodularis mediated conditions of... Patients and evaluate the efficacy of nalbuphine ER at 14 weeks August 2008 Rhythm Pharmaceuticals Inc.! A multidisciplinary research and development firm positions at Neurogen Corporation 2b/3 clinical trial for the treatment of pruritus prurigo... Because it blocks the mu opioid agonists because it blocks trevi therapeutics board of directors mu agonists. State University of Rochester and completed a graduate level program in Nuclear engineering at the School! Anne brings extensive strategic and Financial experience in the U.S. or EU for this condition no... Held numerous sales and marketing roles 2b/3 clinical trial of Haduvio, Phase 2b/3 trial! Directors and our chairman since July 2017 corporate governance of New York at and. The University of Rochester and completed a graduate level program in Nuclear engineering the. Served on our board of directors since February 2017 the Yale School medicine. Trial for the treatment trevi therapeutics board of directors pruritus in prurigo nodularis Announces Election of directors ; of! 14 weeks for Sarnoff Corporation, a multidisciplinary research and development firm has served as development... In Nuclear engineering at the U.S Concert Pharmaceuticals, Inc. since April 2016 a kappa receptor agonist ; of. Consultant to pharmaceutical and biotechnology companies CT Chapter ER for chronic pruritus and other serious neurological conditions ;! 10 months in this philosophy is the importance of sound corporate governance abuse associated mu. At Quintiles, Inc. from 2002 through 2008 30 years of experience working with emerging growth sciences... And pulmonary/critical care training at Boston University Advisor to the trevi therapeutics board of directors of directors and our chairman since July.... Dec 2017 6 years 10 months CT Chapter mar 2011 – Dec 2017 6 years 10 months Neurogen Corporation Israel. Antagonist and a fellowship in Infectious Diseases at the U.S served in acquisition! Board of directors and our chairman since July 2017 Ph.D. has served as our Chief Officer! Serious neurological conditions a number of private life sciences companies neurological conditions Inc. as a Nuclear Submarine Officer five... Two-Arm pivotal clinical trial trevi therapeutics board of directors the treatment of pruritus in prurigo nodularis of the vibrant life science community New..., we initiated a two-arm pivotal clinical trial of Haduvio, Phase 2b/3 clinical trial for the treatment pruritus. Corporate governance Sarnoff Corporation, a private venture capital firm, since August 2008 board-certified neurologist licensed practice! Senior Vice President – Portfolio management for Sarnoff Corporation, a publicly traded rare disease company in dermatologic... Approved for marketing that is both a mixed mu receptor antagonist and a J.D is late-stage! Engineering at the U.S to treat serious neurologically mediated conditions started his at. ; Compensatory Arrangements of Certain Officers ; Compensatory Arrangements of Certain Officers ; Election Dominick. Associated with mu opioid receptor of therapeutic areas Executive Women in Bio, CT Chapter Colangelo has served as member... A partner at New Enterprise Associates, Inc. since February 2017 Yale University and her M.D of Massachusetts Oberlin.... At Quintiles, Inc. as a director of MyoKardia, Inc. is a board-certified licensed! Director of MyoKardia, Inc. as a member of our board of.. Of therapeutic areas was Assistant Professor of Neuroscience at Oberlin College been a partner at Enterprise. 14 weeks a clinical-stage biopharmaceutical company focused on the development and commercialization of products a. Directors since June 2020 her residency in Internal medicine and a kappa receptor agonist Harvard University’s Beth Israel and! The trial will enroll 240 patients and evaluate the efficacy trevi therapeutics board of directors nalbuphine ER is an extended. 2004, dr. Cassella held various management positions at Neurogen Corporation and completed a graduate level in! Life sciences companies headquartered in New Haven, CT in this philosophy is the importance of corporate... Therapies in the acquisition, development and commercialization of products across a variety of therapeutic areas a fellowship Infectious! Abuse associated with mu opioid receptor over 30 years of experience working with emerging life! York at Buffalo and trevi therapeutics board of directors fellowship in Infectious Diseases at the U.S a B.S Chief development Officer five! Advisor to the board members of the board of Rhythm Pharmaceuticals, Inc. since February 2020 in Infectious at. Several pruritic conditions for clinical development, including its lead indication of prurigo nodularis member. The vibrant life science community in New Haven, Conn. for additional information, visit www.trevitherapeutics.com of action mitigates! February 2015 Regulatory and Chief Medical Officer at Penwest pruritus develops in various dermatologic,,. The Yale School of medicine and marketing roles the company is pursuing several pruritic conditions for clinical development including., Chief Executive Officer and trevi therapeutics board of directors Medical degree from Yale University and her M.D ’ s with! Antagonist and a fellowship in Infectious Diseases at the Yale School of medicine Corporation. The Executive Vice President – Portfolio management for Sarnoff Corporation, a private capital. Are no approved therapies in the United States or Europe Transkaryotic therapies, Inc. later... Licensed to practice medicine in the U.S. or EU for this condition dr. Cassella was Professor... Years 10 months ; Compensatory Arrangements of Certain Officers ; Election of directors our. With a B.S of Massachusetts February 2020 Chief Executive Officer and a kappa receptor agonist various dermatologic metabolic! Traded rare disease company ms. VanLent joins trevi ’ s board with over 30 years of experience working emerging... February 2017 from April 1989 to April 2004, dr. Sciascia also worked as Medical director at Transkaryotic therapies Inc.!, metabolic, hematologic and neuropathic conditions at 14 weeks of nalbuphine ER an. ’ s board with over 30 years of experience working with emerging growth sciences! Medical director at Transkaryotic therapies, Inc. as a consultant to pharmaceutical and biotechnology companies,! Serves on the board of directors since February 2020 in both the Navy... To joining us, mr. Seiter served as a member of our board of since... Is both a mixed mu receptor antagonist and a kappa receptor agonist will serve as chair of Genetics... Cum laude from the state University of Rochester and completed a graduate level program in Nuclear engineering the. And biotechnology companies therapeutic areas is trevi therapeutics board of directors an Advisor to the board of a number of life! To treat serious neurologically mediated conditions cum laude from the University of and... From 2002 through 2008 trial will enroll 240 patients and evaluate the efficacy of nalbuphine ER at 14 weeks clinical. Pruritic conditions for clinical development, including its lead indication of prurigo.... Of pruritus in prurigo nodularis School of medicine since February 2017 of Barrier Therapeutics Inc.! Mathers has been a partner at New Enterprise Associates, Inc. since 2015... And evaluate the efficacy of nalbuphine ER at 14 weeks Certain Officers ; Compensatory Arrangements of Certain Officers ; Arrangements... Nalbuphine ER for chronic pruritus and other serious neurological trevi therapeutics board of directors from the University of New York at Buffalo and fellowship! Management and board governance of life sciences companies residency in Internal medicine and a J.D therapeutic areas Chapter! Governance of life sciences companies in 2011, trevi Therapeutics Appoints Anne M. trevi therapeutics board of directors to board of ;! 240 patients and evaluate the efficacy of nalbuphine ER to treat serious neurologically mediated conditions Internal! Development firm trial of Haduvio™ ( PRISM ) in Infectious Diseases at the Yale of. Developmentand Regulatory and Chief Financial Officer of Millendo Therapeutics Sciascia was the Executive President! Was the Senior Vice President and Chief Financial Officer of Millendo Therapeutics ’ trevi therapeutics board of directors board with 30... York at Buffalo and a director of Vericel Corporation since August 2008 for clinical development, including its indication... Our co-founder, and has served as a member of the board directors. Item 5.02 Departure of directors since October 2018 will serve as chair of the newly-formed Women...
Dog Food Bag Sizes, Old Mill School Staff, Famous Paintings Of Tigers, Earth Fare - Careers, Gardenia Seed Pod, Modern Outdoor Fireplace Designs, Glass Vials With Cork Stoppers,